Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience

Paper is devoted to one of the most actual problems of early childhood — a pneumococcal infection. The unique preventive way is vaccination. The authors have demonstrated their own experience with pneumococcal conjugate 7-valent vaccine in 196 children 1–5 years old. A comparative analysis of childr...

Full description

Bibliographic Details
Main Authors:	N. L. Chernaya, O. B. Dadayeva, V. M. Ganuzin, G. S. Ganuzina, S. E. Batorshina, I. V. Ivanova
Format:	Article
Language:	English
Published:	Paediatrician Publishers, LLC 2012-02-01
Series:	Pediatričeskaâ Farmakologiâ
Subjects:	pneumococcal disease vaccination pneumococcal conjugate 7-valent vaccine safety reactogenicity children
Online Access:	https://www.pedpharma.ru/jour/article/view/383

Similar Items

PNEUMOCOCCAL INFECTION VACCINAL PREVENTION EFFICACY IN CHILDREN USING PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE
by: N. L. Chernaya, et al.
Published: (2013-01-01)

Seven-Valent Pneumococcal Conjugate Vaccine and Nasopharyngeal Microbiota in Healthy Children
by: Giske Biesbroek, et al.
Published: (2014-02-01)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: V. K. Tatochenko, et al.
Published: (2012-03-01)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
by: Earnshaw Stephanie R, et al.
Published: (2012-04-01)

Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands
by: Anna M.M. van Deursen, et al.
Published: (2012-11-01)

Pneumococcal meningitis: epidemiological profile pre‐ and post‐introduction of the pneumococcal 10‐valent conjugate vaccine
by: Tatiane E. Hirose, et al.
Published: (2015-03-01)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
by: Filippo Ansaldi, et al.
Published: (2020-01-01)

The cost-effectiveness of 13-valent pneumococcal conjugate vaccine for older adults : a systematic review
by: Wong, Kwan-ting, et al.
Published: (2014)

Comparison of Post-Licensure Safety Surveillance of 13-Valent Pneumococcal Conjugate Vaccine and 7-Valent Pneumococcal Conjugate Vaccine: Data from the Vaccine Advere Event Reporting System (Vaers)
by: Arana, Jorge E
Published: (2011)

EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN
by: M. V. Fedoseenko, et al.
Published: (2014-09-01)

EFFECTIVENESS OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE: EMERGING DATA FROM INVASIVE PNEUMOCOCCAL DISEASE, PNEUMONIA, ACUTE OTITIS MEDIA AND NASOPHARYNGEAL CARRIAGE
by: Ralf Rene Reinert, et al.
Published: (2012-06-01)

Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children
by: Corinne Levy, et al.
Published: (2021-08-01)

Evolution, Clinical and Microbiological Characteristics of Invasive Pneumococcal Disease since the Introduction of the Pneumococcal Conjugate Vaccine 13-Valent in Adults over 18 Years Old
by: Juan Buades, et al.
Published: (2021-01-01)

Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines
by: Hyunju Lee, et al.
Published: (2014-02-01)

PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION
by: A. V. Rudakova, et al.
Published: (2014-01-01)

Childhood invasive pneumococcal disease caused by non-7-valent pneumococcal vaccine (PCV7) serotypes under partial immunization in Taiwan
by: Ching-Fen Shen, et al.
Published: (2013-09-01)

Evolution of pneumococcal infections in adult patients during a four-year period after vaccination of a pediatric population with 13-valent pneumococcal conjugate vaccine
by: Antoni Payeras, et al.
Published: (2015-04-01)

Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ
by: Starla Hayward, et al.
Published: (2016-04-01)

Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren’s syndrome without disease modifying treatment
by: Per Nived, et al.
Published: (2018-04-01)

Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands
by: Mirjam J. Knol, et al.
Published: (2015-11-01)

NEXT GENERATION PNEUMOCOCCAL CONJUGATE VACCINES EFFICACY AND EFFECTIVENESS IN DIFFERENT REGIONS OF THE WORLD
by: O. P. Kovtun, et al.
Published: (2014-01-01)

Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data
by: Strutton David R, et al.
Published: (2012-08-01)

Clinical Efficacy of Pneumococcal Conjugate 13-valent Vaccine in Young Children
by: S. M. Kharit, et al.
Published: (2016-12-01)

Predictors of pneumococcal carriage and the effect of the 13-valent pneumococcal conjugate vaccination in the Western Australian Aboriginal population
by: Deirdre A. Collins, et al.
Published: (2017-09-01)

Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children of Serotypes Included in Candidate Extended-Spectrum Conjugate Vaccines
by: Shalom Ben-Shimol, et al.
Published: (2021-01-01)

Lessons learnt after the introduction of the seven valent-pneumococcal conjugate vaccine toward broader spectrum conjugate vaccines
by: Oana Falup-Pecurariu
Published: (2012-12-01)

Bronchopulmonary Pathology Prevalence Among Premature infants and Estimation of Prophylactic Efficacy and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Premature infants with Bronchopulmonary Dysplasia
by: Vladislav V. Semerikov, et al.
Published: (2020-02-01)

Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan
by: Ching-Fen Shen, et al.
Published: (2021-09-01)

Re-Analysis of Modeling a Switch from a 13-Valent to 10-Valent Pneumococcal Conjugate Vaccine in Canada: Leveraging Real-World Experience from Belgium
by: Matt D. Wasserman, et al.
Published: (2018-11-01)

Economic evaluation of the second generation pneumococcal conjugate vaccine in children : a systematic review
by: Fan, Hiu-yan, et al.
Published: (2014)

Direct and indirect effects of 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in children hospitalised with pneumonia from formal and informal settlements in Mongolia: an observational study
by: Jocelyn Chan, et al.
Published: (2021-10-01)

The Analysis of Scientific Data on the Efficacy of Pneumococcal Conjugated Vaccine in the Cohort of Children with Bronchial Asthma
by: Tatiana A. Kaliuzhnaia, et al.
Published: (2020-11-01)

Efficacy of 13-valent pneumococcal conjugate vaccine in healthcare workers
by: L A Shpagina, et al.
Published: (2018-11-01)

Prevalence of pneumococcal nasopharyngeal colonization and serotypes circulating in Cameroonian children after the 13-valent pneumococcal conjugate vaccine introduction
by: John Njuma Libwea, et al.
Published: (2020-09-01)

Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children
by: Anita H. J. van den Biggelaar, et al.
Published: (2019-02-01)

Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae
by: Allison E.B. Turner, et al.
Published: (2017-03-01)

Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children
by: Matt Wasserman, et al.
Published: (2021-06-01)

Effects of Pneumococcal Conjugate Vaccine 2 Years after Its Introduction, the Netherlands
by: Gerwin D. Rodenburg, et al.
Published: (2010-05-01)

Impact of Pneumococcal Conjugate Vaccine Thirteen Valent on the Reduction of Invasive Pneumococcal Disease
by: Coulibaly, Aissata
Published: (2016)

Efficacy of usage of pneumococcal 7-valent vaccine in prophylaxis of pneumococcal infection in Novosibirsk children from risk groups
by: O. A. Beletskaya, et al.
Published: (2013-03-01)